Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | DRD2 | P14416 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8351022 | 0.86 | HRH3 (0.61) | HRH3 | |
| SCHEMBL4576188 | 0.82 | DRD2 (0.49) | HRH3DRD2KDM4EGAASIGMAR1 | |
| SCHEMBL8351016 | 0.81 | DRD2 (0.44) | HRH3DRD2KDM4EGAASIGMAR1 | |
| SCHEMBL8352031 | 0.80 | DRD2 (0.49) | HRH3DRD2KDM4EGAASIGMAR1 | |
| SCHEMBL1809859 | 0.80 | KDM4E (0.63) | DRD2KDM4EGAASIGMAR1HSD17B10 | |
| SCHEMBL22419324 | 0.77 | POLB (0.43) | HRH3DRD2KDM4EGAASIGMAR1 | |
| SCHEMBL8352496 | 0.77 | DRD2 (0.50) | DRD2KDM4EGAASIGMAR1HSD17B10 | |
| SCHEMBL25839407 | 0.77 | SLC6A2 (0.50) | DRD2KDM4EGAASIGMAR1HSD17B10 | |
| SCHEMBL4576516 | 0.77 | DRD2 (0.46) | DRD2KDM4EGAASIGMAR1HSD17B10 | |
| SCHEMBL23922764 | 0.76 | ALDH1A1 (0.58) | DRD2KDM4EGAASIGMAR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | NOVARTIS AG (CH) | 2008-09-11 | — | — | US | disclosed |
| EP-1931994-A2 | MOLECULAR MARKERS ASSOCIATED WITH BONE METASTASIS | Novartis AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | MISSBACH MARTIN | 2007-06-14 | — | — | US | disclosed |
| WO-2007038397-A2 | MOLECULAR MARKERS ASSOCIATED WITH BONE METASTASIS | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
| US-20060281714-A1 | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | ZIMMERMANN JOHANN | 2006-12-14 | — | — | US | disclosed |
| EP-1423121-B1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-7112589-B2 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2006-09-26 | — | — | US | disclosed |
| EP-1686995-A1 | USE OF CATHEPSIN K INHIBITORS FOR TREATING OF SEVERE BONE LOSS DISEASES | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| EP-1651238-A1 | COMBINATIONS OF A CATHEPSIN K INHIBITOR AND A BISPHOPHONATE IN THE TREATMENT OF BONE METASTASIS, TUMOR GROWTH AND TUMOR-INDUCED BONE LOSS | Novartis AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | ALTMANN EVA | 2006-04-06 | — | — | US | disclosed |
| WO-2005049028-A1 | USE OF CATHEPSIN K INHIBITORS IN SEVERE BONE LOSS DISEASES | NOVARTIS AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005014006-A1 | COMBINATIONS OF A CATHEPSIN K INHIBITOR AND A BISPHOPHONATE IN THE TREATMENT OF BONE METASTASIS, TUMOR GROWTH AND TUMOR-INDUCED BONE LOSS | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1423121-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135448-A1 | Use of cathepsin k inhibitors for treating of severe bone loss diseases | CTSK, CTSB, CTSZ | HRH3 1523/4885DRD2 4681/4885KDM4E 1710/4885 |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | HRH3 2007/4885DRD2 4763/4885KDM4E 1219/4885 |
| US-20060281714-A1 | Combinations of a cathepsin k inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss | CTSK, CTSB, CTSZ | HRH3 1308/4885DRD2 4518/4885KDM4E 2946/4885 |
| US-20080219996-A1 | Molecular Markers Associated with Bone Metastasis | BST2, BSG, CD44 | HRH3 4026/4885DRD2 4666/4885KDM4E 4385/4885 |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | HRH3 1951/4885DRD2 4752/4885KDM4E 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.